Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3951
Norwood Financial Corp
NWFL
$367M
| $383K | ﹤0.01% |
13,656
+1,518
| +13% | +$41.4K |
2022 Q3
13 quarters
|
|
3952
iShares MSCI Canada ETF
EWC
$7B
| $383K | ﹤0.01% |
7,099
-73,810
| -91% | -$3.82M |
2013 Q2
50 quarters
|
|
3953
Flotek Industries
FTK
$1.12B
| $383K | ﹤0.01% |
22,204
+1,351
| +6% | +$21.4K |
2024 Q3
5 quarters
|
|
3954
Lifecore Biomedical
LFCR
$248M
| $382K | ﹤0.01% |
46,696
+6,124
| +15% | +$45.3K |
2024 Q2
6 quarters
|
|
3955
Global Water Resources
GWRS
$234M
| $382K | ﹤0.01% |
45,186
+1,784
| +4% | +$16.8K |
2019 Q1
27 quarters
|
|
3956
Barclays
BCS
$79.1B
| $382K | ﹤0.01% |
15,000
+14,977
| +65,117% | +$332K |
2013 Q2
50 quarters
|
|
|
TBI
3957
Trueblue
TBI
$279M
| $382K | ﹤0.01% |
83,882
+4,245
| +5% | +$21.8K |
2013 Q2
50 quarters
|
|
3958
ProKidney
PROK
$359M
| $381K | ﹤0.01% |
170,001
+170,000
| +17,000,000% | +$447K |
2023 Q2
10 quarters
|
|
3959
GoPro
GPRO
$279M
| $380K | ﹤0.01% |
269,766
+149,792
| +125% | +$272K |
2014 Q3
45 quarters
|
|
3960
Pulse Biosciences
PLSE
$3.42B
| $380K | ﹤0.01% |
27,652
+2,164
| +8% | +$33.7K |
2017 Q1
35 quarters
|
|
|
STLN
3961
Starling Oncology
STLN
$647M
| $379K | ﹤0.01% |
106,452
+20,605
| +24% | +$76.4K |
2025 Q2
2 quarters
|
|
3962
Aura Biosciences
AURA
$632M
| $378K | ﹤0.01% |
69,298
+4,366
| +7% | +$25.9K |
2022 Q1
15 quarters
|
|
3963
The Honest Company
HNST
$554M
| $378K | ﹤0.01% |
146,330
+14,876
| +11% | +$45.6K |
2024 Q2
6 quarters
|
|
3964
Televisa
TV
$1.21B
| $377K | ﹤0.01% |
129,573
+82,256
| +174% | +$225K |
2025 Q3
1 quarter
|
|
3965
Unisys
UIS
$166M
| $377K | ﹤0.01% |
136,550
+9,461
| +7% | +$29.6K |
2013 Q2
50 quarters
|
|
|
TRUE
3966
DELISTED
TrueCar
TRUE
| $377K | ﹤0.01% |
166,628
+13,972
| +9% | +$30K |
2016 Q1
39 quarters
|
|
3967
Hawthorn Bancshares
HWBK
$283M
| $376K | ﹤0.01% |
10,789
+2,073
| +24% | +$66.3K |
2024 Q3
5 quarters
|
|
3968
New Fortress Energy
NFE
$37.5M
| $374K | ﹤0.01% |
6,568
+1,805
| +38% | +$133K |
2021 Q3
17 quarters
|
|
3969
Asure Software
ASUR
$222M
| $371K | ﹤0.01% |
39,357
+3,033
| +8% | +$25.5K |
2023 Q1
11 quarters
|
|
3970
Cricut
CRCT
$1.37B
| $371K | ﹤0.01% |
74,896
+10,116
| +16% | +$51.6K |
2023 Q2
10 quarters
|
|
3971
Bassett Furniture
BSET
$179M
| $371K | ﹤0.01% |
22,107
+3,897
| +21% | +$61.1K |
2022 Q3
13 quarters
|
|
3972
Concrete Pumping Holdings
BBCP
$496M
| $370K | ﹤0.01% |
55,108
+4,873
| +10% | +$32K |
2019 Q1
27 quarters
|
|
3973
Resources Connection
RGP
$134M
| $370K | ﹤0.01% |
73,339
+5,161
| +8% | +$24.6K |
2016 Q2
38 quarters
|
|
3974
Limoneira
LMNR
$217M
| $369K | ﹤0.01% |
29,250
+82
| +0.3% | +$1.16K |
2022 Q3
13 quarters
|
|
3975
C&F Financial
CFFI
$320M
| $369K | ﹤0.01% |
5,086
+644
| +14% | +$44.9K |
2023 Q2
10 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.